[1]吕宗峻,李春海,王晓东.胃癌患者血清miR-216b 和miR-132 水平表达与临床预后的关系研究[J].现代检验医学杂志,2024,39(03):98-102+141.[doi:10.3969/j.issn.1671-7414.2024.03.016]
　L? Zongjun,LI Chunhai,WANG Xiaodong.Relationship between the Expression of Serum miR-216b and miR-132 Levels and Clinical Prognosis in Patients with Gastric Cancer[J].Journal of Modern Laboratory Medicine,2024,39(03):98-102+141.[doi:10.3969/j.issn.1671-7414.2024.03.016]
点击复制

胃癌患者血清miR-216b 和miR-132 水平表达与临床预后的关系研究()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第39卷
期数:
2024年03期
页码:
98-102+141
栏目:
论著
出版日期:
2024-05-15

文章信息/Info

Title:
Relationship between the Expression of Serum miR-216b and miR-132 Levels and Clinical Prognosis in Patients with Gastric Cancer
文章编号:
1671-7414（2024）03-098-06
作者:
吕宗峻; 李春海; 王晓东
（佳木斯市中心医院普外二科，黑龙江佳木斯 154002）
Author(s):
L? Zongjun;  LI Chunhai;  WANG Xiaodong
（Department 2 of General Surgery, Jiamusi Central Hospital, Heilongjiang Jiamusi 154002, China）
关键词:
胃癌; 微小核糖核酸-216b; 微小核糖核酸-132
分类号:
R735.2；R730.43
DOI:
10.3969/j.issn.1671-7414.2024.03.016
文献标志码:
A
摘要:
目的 探讨胃癌患者血清miR-216b 和miR-132 水平表达与临床预后的关系。方法 选取2018 年1 月～ 2020年2 月在佳木斯市中心医院就诊的87 例胃癌患者作为胃癌组，选择同期87 例健康体检者作为对照组。实时荧光定量PCR（quantitative real-time PCR，qRT- PCR）检测血清中miR-216b 和miR-132 表达水平，分析胃癌患者血清miR-216b和miR-132 表达水平与临床病理特征的关系。根据胃癌患者随访期间的生存或死亡情况，将胃癌患者分为预后良好组（生存，n=51）和预后不良组（死亡，n=36），用受试者工作特征（receiver operating characteristic，ROC）曲线分析血清miR-216b 和miR-132 表达水平对胃癌患者预后的预测价值；COX 回归分析影响胃癌患者预后的因素。结果 与对照组比较，胃癌组血清中miR-216b（0.69 ± 0.20 vs 1.02 ± 0.24）和miR-132（0.73 ± 0.19 vs 1.01 ± 0.22）表达水平降低，差异具有统计学意义（t=9.853，8.984，均P<0.001）。分化程度为低分化、TNM 分期为III±IV 期、有淋巴结转移、有远处转移的胃癌患者血清miR-216b，miR-132 表达水平低于分化程度为中、高分化、TNM 分期为I±II 期、无淋巴结转移、无远处转移的胃癌患者，差异具有统计学意义（t=6.266，3.412，2.890，2.723；4.999，3.734，4.180，5.502，均P ＜ 0.05）。与预后良好组比较，预后不良组胃癌患者血清中miR-216b（0.56 ± 0.16 vs 0.78 ± 0.23）和miR-132（0.60± 0.11 vs 0.82 ± 0.25）表达水平降低，差异具有统计学意义（t=4.952，4.946，均P<0.001）。血清miR-216b，miR-132 及二者联合预测胃癌患者预后的曲线下面积（area under the cure，AUC）分别为0.797（95%CI:0.706 ～ 0.889），0.832（95%CI:0.745 ～ 0.918）和0.900（95%CI:0.836 ～ 0.964）；敏感度和特异度分别为83.3%，68.6%；97.2%，62.7% 和79.4%，72.5%；当血清miR-216b，miR-132 预测胃癌患者预后不良的截断值分别为0.66，0.76 时，预测的敏感度较高。COX 回归分析显示，miR-216b 低表达、miR-132 低表达、分化程度为低分化、TNM 分期为III+IV 期、有淋巴结转移、有远处转移是胃癌患者预后不良的危险因素（均P ＜ 0.05）。结论 miR-216b 和miR-132 在胃癌患者血清中呈低表达，二者可作为预测胃癌患者预后的有效生物标志物。
Abstract:
Objective To investigate the relationship between serum microRNAs（miRNAs, miR）-216b and miR-132 expressions and clinical prognosis in patients with gastric cancer. Methods From January 2018 to February 2020, 87 gastric cancer patients who visited Jiamusi Central Hospital were selected as the gastric cancer group, while 87 healthy individuals who underwent physical examinations in the hospital were collected as the control group. Quantitative real-time PCR（qRT- PCR） was applied to detect the expression levels of miR-216b and miR-132 in serum. The relationship between the expression levels of miR-216b and miR-132 in the serum of gastric cancer patients and their clinical pathological characteristics was analyzed. According to the survival or death status of gastric cancer patients during the follow-up period, these patients were divided into a good prognosis group(survival, n=51) and a poor prognosis group(death, n=36). The predictive value of serum miR-216b and miR-132 expression levels on the prognosis of gastric cancer patients was analyzed using the receiver operating characteristic (ROC) curve. COX regression was applied to analyze factors affecting the prognosis of gastric cancer patients. Results Compared with the control group，the expression levels of miR-216b（ 0.69 ± 0.20 vs 1.02 ± 0.24） and miR-132（0.73 ± 0.19 vs 1.01 ± 0.22）in serum of gastric cancer group were decreased, and the differences were significant (t=9.853, 8.984, all P<0.001). The expression levels of miR-216b and miR-132 in serum of gastric cancer patients with low differentiation,TNM stages III ±IV, lymph node metastasis, and distant metastasis were significantly lower than those of gastric cancer patients with medium and high differentiation, TNM stages I±II, no lymph node metastasis and no distant metastasis, and the differences were statistically significant (t=6.266, 3.412, 2.890, 2.723; 4.999, 3.734, 4.180, 5.502, all P<0.05). Compared with the good prognosis group, the expression levels of miR-216b（0.56 ± 0.16 vs 0.78 ± 0.23）and miR-132（0.60 ± 0.11 vs 0.82 ± 0.25） in serum of gastric cancer patients in the poor prognosis group were decreased, and the differences were statistically significant (t=4.952, 4.946, all P<0.001). The areas under the cure (AUC) of serum miR-216b, miR-132 and their combination predicted the prognosis of gastric cancer patients was 0.797 (95%CI:0.706 ～ 0.889), 0.832 (95%CI:0.745 ～ 0.918) and 0.900 (95%CI:0.836 ～ 0.964), respectively. The sensitivity and specificity were 83.3%, 68.6%; 97.2%, 62.7% and 79.4%, 72.5%, respectively. When the cut-off values of serum miR-216b and miR-132 for predicting poor prognosis of gastric cancer patients were 0.66 and 0.76, respectively, the sensitivity of the prediction were relatively high. COX regression analysis showed that low expression of miR-216b and miR-132, poorly differentiated degree, TNM stage III+IV, lymph node metastasis, and distant metastasis were risk factors for poor prognosis in gastric cancer patients (all P<0.05). Conclusion MiR-216b and miR-132 were low expressed in the serum of gastric cancer patients, and they could serve as effective biomarkers for predicting the prognosis of gastric cancer patients.

参考文献/References:

[1] SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA-A Cancer Journal for Clinicians,2021, 71(3): 209-249.
[2] RAWLA P, BARSOUK A. Epidemiology of gastric cancer: global trends, risk factors and prevention[J].Przeglad Gastroenterologiczny, 2019, 14(1): 26-38.
[3] JAFARZADEH A, NOORI M, SARRAFZADEH S,et al. MicroRNA-383: a tumor suppressor miRNA in human cancer[J]. Frontiers in Cell and Developmental Biology, 2022, 10: 955486.
[4] WANG Wei, YANG Tao, LI Dongsheng, et al. LINC00491 promotes cell growth and metastasis through miR-324-5p/ROCK1 in liver cancer[J]. Journal of Translational Medicine, 2021, 19(1): 504.
[5] HUA Jinghan, WANG Xiaolin, MA Liying, et al. CircVAPA promotes small cell lung cancer progression by modulating the miR-377-3p and miR-494-3p/IGF1R/AKT axis[J]. Molecular Cancer, 2022, 21(1):123.
[6] TANG Xingkui, LIN Yukun, HE Jialin, et al. Downregulated miRNA-491-3p accelerates colorectal cancer growth by increasing uMtCK expression[J].PeerJ, 2022, 10: e14285.
[7] FAN Huining, CHEN Zhaoyu, CHEN Xiaoyu, et al. METTL14-mediated m6A modification of circORC5 suppresses gastric cancer progression by regulating miR-30c-2-3p/AKT1S1 axis[J]. Molecular Cancer,2022, 21(1): 51.
[8] LI Tian, GUO Dong, XU Xiaoyan, et al. MicroRNA153 may act as a potential biomarker and prognostic indicator of patients with gastric cancer[J]. Oncology Letters, 2023, 26(1): 278-286.
[9] LIU Xianchen, XU Dong, XU Xiaodong, et al. MiR-216b regulates the tumorigenesis of gastric cancer by targeting PXN[J]. Pathology Research and Practice,2021, 218: 153325.
[10] LI Ping, WANG Liuhua, LI Pengfei, et al. Silencing LncRNA XIST exhibits antiproliferative and proapoptotic effects on gastric cancer cells by upregulating microRNA-132 and down-regulating PXN[J]. Aging, 2020, 13(10): 14469-14481.
[11] 中华人民共和国国家卫生和计划生育委员会. 胃癌规范化诊疗指南(试行)[J]. 中国医学前沿杂志(电子版), 2013, 5(8): 29-36. National Health and Family Planning Commission of the People’s Republic of China. Standardized diagnosis and treatment guidelines for gastric cancer(trial)[J]. Chinese Journal of the Frontiers of Medical Science(Electronic Version), 2013, 5(8): 29-36.
[12] 郝美玲, 张秀芬, 李子鑫, 等. 胃癌组织中MLH1,MSH2, MSH6 和PMS2 表达及与临床病理特征和预后的相关性分析[J]. 现代检验医学杂志, 2023, 38(2): 48-51, 62. HAO Meiling, ZHANG Xiufen, LI Zixin, et al. Correlation between the expression of MLH1, MSH2,MSH6, PMS2 and clinicopathological features and prognosis in gastric cancer[J]. Journal of Modern Laboratory Medicine, 2023, 38(2): 48-51, 62.
[13] AJANI J A, D’AMICO T A, BENTREM D J, et al. Gastric cancer, version 2.2022, NCCN clinical practice guidelines in oncology[J]. Journal of the National Comprehensive Cancer Network, 2022, 20(2): 167-192.
[14] ZHAO Xia, YU Zhihao, ZANG Ku. Platelet-derived growth factors affect clinical features and prognosis of gastric cancer[J]. Journal of Oncology, 2022, 2022:2108368.
[15] ZOU Jun, WU Boyu, LIN Chao, et al. MiR-216b targets CPEB4 to suppress colorectal cancer progression through inhibiting IL-10-mediated M2 polarization of tumor-associated macrophages[J]. American Journal of Translational Research, 2022, 14(11): 8129-8145.
[16] ZHU Guomin, CHEN Shaoqin, JIANG Qunguang, et al. MiR-216b inhibits gastric cancer proliferation and migration by targeting PARK7[J]. Indian Journal of Pathology & Microbiology, 2021, 64(1): 52-57.
[17] ZHANG Weitong, WANG Zhenfen, CAI Guohao, et al. Circ_DOCK1 regulates USP11 through miR-132-3p to control colorectal cancer progression[J]. World Journal of Surgical Oncology, 2021, 19(1): 67.
[18] LIU Bingtian, QIANG Ling, GUAN Bingxin, et al. Targeting kinesin family member 21B by miR-132-3p represses cell proliferation, migration and invasion in gastric cancer[J]. Bioengineered, 2022, 13(4): 9006-9018.
[19] 姚晓慧. 胃癌组织miRNA-539 和miRNA-4317 水平与患者预后的相关性[J]. 中国民康医学, 2022, 34(21): 132-134. YAO Xiaohui. Correlations among miRNA-539 and miRNA-4317 levels in gastric cancer tissues and prognosis[J]. Medical Journal of Chinese People’s Health, 2022, 34(21): 132-134.
[20] 黄莉. MiR-216b-5p 靶向TRIM44 抑制PI3K/AKT/mTOR 通路调控肝癌细胞生物学功能的机制研究[D]. 南宁：广西医科大学, 2021. HUANG Li. The mechanism of miR-216b-5p targeting TRIM44 to inhibit the PI3K/AKT/mTOR pathway and regulate the biological function of liver cancer cells[D].Nanning: Guangxi Medical University, 2021.
[21] IBRAHIM H M, ISMAIL M B, AMMAR R B, et al. Thidiazuron suppresses breast cancer via targeting miR-132 and dysregulation of the PI3K-Akt signaling pathway mediated by the miR-202-5p-PTEN axis[J].Biochemistry and Cell Biology, 2021, 99(3): 374-384.

相似文献/References:

[1]包安裕.血清25-(OH)D水平在胃癌患者中的临床意义[J].现代检验医学杂志,2016,31(02):133.[doi:10.3969/j.issn.1671-7414.2016.02.040]
　BAO An-yu.Clinical Significance of Serum 25-Hydroxyvitamin D Level of Gastric Cancer Patients[J].Journal of Modern Laboratory Medicine,2016,31(03):133.[doi:10.3969/j.issn.1671-7414.2016.02.040]
[2]郑齐锶,严留佳,王庆飞,等.骨形态发生蛋白-7在胃癌组织中的表达及意义[J].现代检验医学杂志,2015,30(06):18.[doi:10.3969/j.issn.1671-7414.2015.06.005]
　ZHENG Qi-si,YAN Liu-jia,WANG Qing-fei,et al.Expression and Clinical Significance of Bone Morphogenetic Protein-7 in Gastric Cancer[J].Journal of Modern Laboratory Medicine,2015,30(03):18.[doi:10.3969/j.issn.1671-7414.2015.06.005]
[3]张艳梅,马靖华,刘阳晨,等.中国人群miR-449a单核苷酸多态性与胃癌易感性的相关性研究[J].现代检验医学杂志,2016,31(04):14.[doi:10.3969/j.issn.16717-414.2016.04.004]
　ZHANG Yan-mei,MA Jing-hua,LIU Yang-chen,et al.Correlation Study on miR-449a Gene Polymorphism of Single Nucleotide and Susceptibility to Gastric Cancer in A Chinese Han Population[J].Journal of Modern Laboratory Medicine,2016,31(03):14.[doi:10.3969/j.issn.16717-414.2016.04.004]
[4]桂 林,黄远帅.血清CA72-4,CA242,CA19-9和CEA的PCA-决策树模型对胃癌的诊断价值[J].现代检验医学杂志,2017,32(01):57.[doi:10.3969/j.issn.1671-7414.2017.01.016]
　GUI Lin,HUANG Yuan-shuai.Diagnostic Value of Serum CA72-4,CA242,CA19-9 and CEA for Gastric Cancer Based on PCA-Decision Tree Model[J].Journal of Modern Laboratory Medicine,2017,32(03):57.[doi:10.3969/j.issn.1671-7414.2017.01.016]
[5]朱文芳,沈建军,付 涛,等.血清GPDA联合肿瘤标志物对胃癌早期诊断的临床价值[J].现代检验医学杂志,2017,32(04):110.[doi:10.3969/j.issn.1671-7414.2017.04.031]
　ZHU Wen-fang,SHEN Jian-jun,FU Tao,et al.Clinical Value of Serum GPDA Associated Tumor Markers for Early Diagnosis of Gastric Cancer[J].Journal of Modern Laboratory Medicine,2017,32(03):110.[doi:10.3969/j.issn.1671-7414.2017.04.031]
[6]田文静,刘电力,刘惠敏,等.人血清幽门螺杆菌SodB抗体检测与胃癌发生的相关性研究[J].现代检验医学杂志,2018,33(01):22.[doi:10.3969/j.issn.1671-7414.2018.01.001]
　TIAN Wen-jing,LIU Dian-li,LIU Hui-min,et al.Correlative Study between Detection of Human Serum Helicobacter Pylori SodB Antibody and the Occurrence of Gastric Cancer[J].Journal of Modern Laboratory Medicine,2018,33(03):22.[doi:10.3969/j.issn.1671-7414.2018.01.001]
[7]靳庆娥,苏建荣.北京地区汉族人群胃癌发生与EBVA73基因外显子区A157154C多态性的相关性研究[J].现代检验医学杂志,2018,33(03):5.[doi:10.3969/j.issn.1671-7414.2018.03.002]
　JIN Qing-e,SU Jian-rong.Association of Epstein-Barr Virus A73 Gene Extron A157154C Single Nucleotide Polymorphism with Gastric Carcinoma in Han Population of Beijing Area[J].Journal of Modern Laboratory Medicine,2018,33(03):5.[doi:10.3969/j.issn.1671-7414.2018.03.002]
[8]陈绪阳a,吉茂礼b,刘雪花b,等.外周血MPV,PDW与血清CEA联合检测对胃癌和胃溃疡的鉴别诊断作用[J].现代检验医学杂志,2019,34(01):107.[doi:10.3969/j.issn.1671-7414.2019.01.028]
　CHEN Xu-yanga,JI Mao-lib,LIU Xue-huab,et al.Differential Diagnosis of Gastric Cancer and Gastric Ulcer by Joint Detection of Peripheral Blood MPV，PDW and Serum[J].Journal of Modern Laboratory Medicine,2019,34(03):107.[doi:10.3969/j.issn.1671-7414.2019.01.028]
[9]张筱东,谢星星,李　佳,等.血清外泌体 miR-221 和 miR-378 水平检测在胃癌诊断中的应用研究[J].现代检验医学杂志,2020,35(06):52.[doi:doi:10.3969/j.issn.1671-7414.2020.06.013]
　ZHANG Xiao-dong,XIE Xing-xing,LI Jia,et al.Application Study of Serum Exosome miR-221 and miR-378 Detection in theDiagnosis of Gastric Cancer[J].Journal of Modern Laboratory Medicine,2020,35(03):52.[doi:doi:10.3969/j.issn.1671-7414.2020.06.013]
[10]徐翠香,王建华,武　敏,等.胃癌患者血清CA724，NSE和 PGR水平联合检测对肿瘤临床病理分期及淋巴结转移的诊断价值[J].现代检验医学杂志,2021,36(01):6.[doi:10.3969/j.issn.1671-7414.2021.01.002]
　XU Cui-xiang,WANG Jian-hua,WU Min,et al.Diagnostic Value of Combined Detection of Serum CA724, NSE and PGR Levels in Patients with Gastric Cancer for Tumor Clinical Pathological Stage and Lymph Node Metastasis[J].Journal of Modern Laboratory Medicine,2021,36(03):6.[doi:10.3969/j.issn.1671-7414.2021.01.002]

备注/Memo

备注/Memo:
基金项目： 黑龙江卫生健康委科研项目（合同书）（编号：2020-365）。
作者简介：吕宗峻（1989-），男，硕士研究生，主治医师，研究方向：胃肠外科微创治疗，E-mail：ulch1o@163.com。
更新日期/Last Update: 2024-05-15